Fuchs, Michael and Jacob, Anne Sophie and Kaul, Helen and Kobe, Carsten and Kuhnert, Georg and Pabst, Thomas and Greil, Richard and Broeckelmann, Paul J. and Topp, Max S. and Just, Marianne and Hertenstein, Bernd and Soekler, Martin and Vogelhuber, Martin and Zijlstra, Josee M. and Keller, Ulrich Bernd and Krause, Stefan W. and Duehrsen, Ulrich and Meissner, Julia and Viardot, Andreas and Eich, Hans-Theodor and Baues, Christian and Diehl, Volker and Rosenwald, Andreas and Buehnen, Ina and von Tresckow, Bastian and Dietlein, Markus and Borchmann, Peter and Engert, Andreas and Eichenauer, Dennis A. (2023) Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. SPRINGERNATURE, LONDON.
Full text not available from this repository. (Request a copy)Abstract
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS >= 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.
| Item Type: | Other |
|---|---|
| Uncontrolled Keywords: | STUDY-GROUP HD7; ABVD CHEMOTHERAPY; RADIATION-THERAPY; RADIOTHERAPY; RELAPSE; INTENSITY; RISK; CURE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 07 May 2024 06:20 |
| Last Modified: | 07 May 2024 06:20 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60871 |
Actions (login required)
 |
View Item |
